PABLO J. CAGNONI, M.D.
President, Onyx Pharmaceuticals, Inc., a subsidiary of Amgen
Pablo J. Cagnoni, M.D., was named President of Onyx Pharmaceuticals, Inc. following Amgen's acquisition of Onyx in October 2013. Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations. Prior to joining Onyx, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. He played a key role in the U.S., European and Japanese regulatory submissions and approvals of Afinitor®, Tasigna®, Signifor®, Exjade®, Jakavi® and Glivec® in various indications. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, and prior to that Chief Medical Officer of OSI Pharmaceuticals. Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program.
Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology in Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.